Hodgkin disease/lymphoma (HD/HL) is an uncommon malignancy; in 2008, an estimated 8220 new diagnoses and 1350 deaths will occur in the United States. The past few decades have seen significant progress in the management of HL; it is now curable in at least 80% of patients. In fact, cure rates for HL have increased so extensively that the overriding treatment considerations often relate to long-term toxicity, especially for patients with early- or intermediate-stage disease. The World Health Organization classification divides HL into 2 main types: classical and lymphocyte-predominant HL (CHL and LPHL). These guidelines discuss clinical management, focusing exclusively on patients from postadolescence through the seventh decade of life who do not have serious intercurrent disease.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center was designated one of the first 11 “comprehensive” cancer centers in 1972. Since then, the Center has become a national leader in research, treatment, and education.
Today, the UAB Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated cancer center in a 5-state region: Alabama, Arkansas, Georgia, Louisiana, and Mississippi.
The Center, which emphasizes multidisciplinary research and patient care, has grown to more than 300 faculty members (including basic and clinical scientists and physicians). It encompasses more than 150,000 square feet of research space and has more than $100 million in annual research funding. Faculty expertise includes tumor biology, virology/gene therapy, immunobiology, targeted immunotherapy, drug discovery and experimental therapeutics. Cancer Center Director Edward Partridge, MD (second photo on cover), is a nationally recognized expert in the fields of women's cancers and outreach among minorities and underserved populations.
UAB is the recipient of 3 NCI SPORE (Specialized Program of Research Excellence) grants: breast, brain tumor, and pancreatic cancer (P20).